AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron
AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals with Chinese drug developers. The Harbour BioMed and Syneron Bio...
View ArticleAstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China
AstraZeneca is again boosting its manufacturing footprint in China, this time making a $2.5 billion investment to build its first vaccine plant and second R&D facility in the country. As a part of...
View ArticleGenfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval
Plus, news about Akeso, Pulmatrix, Autolus, MacroGenics and BlissBio: Genfit completes up to €185M royalty deal: Per the agreement with HealthCare Royalty, the company gets €130 million ($141 million)...
View ArticleFDA approves Novartis’ Fabhalta in C3 glomerulopathy
Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 glomerulopathy. Fabhalta is the first drug approved specifically to treat C3...
View ArticleThe buildup to Chimerix's $935M cash exit to Jazz
Chimerix began attracting deal interest in its experimental brain tumor treatment about 18 months before it signed a $935 million cash exit to Jazz Pharmaceuticals earlier this month, according to a...
View ArticleBARDA cancels annual Industry Day
An annual gathering of industry and government officials focused on biomedical countermeasures and pandemic response has been canceled. The two-day event hosted by the Biomedical Advanced Research and...
View ArticleAlnylam hopes its ATTR-CM label will give Amvuttra an edge
Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for its newly-approved Amvuttra indication may give it an advantage over its...
View ArticleTrump think tank resurrects international drug pricing policy
President Donald Trump appears poised to bring back one of the drug pricing policies from his first term, as part of efforts to go after other countries "freeloading" on US pharma innovation. A
View ArticleLiver cancer drug combo gets its second FDA rejection
The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug combination to treat the most common form of liver cancer. Korean biotech HLB and China-based Hengrui were applied to...
View ArticleTeenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win,...
Hello and welcome back to the new Endpoints Weekly. It was another busy week in the biopharma world and we’ve got all of the headlines for you below. We also had an
View ArticleBelgian biotech Augustine gets $85M for neuro and cardiometabolic pills
Augustine Therapeutics has reeled in €77.7 million (about $85 million) to take on Charcot-Marie-Tooth disease, neurodegenerative conditions and cardiometabolic disorders. Two of Europe's leading...
View Article23andMe files for bankruptcy, CEO Wojcicki steps down
Rounding off a turbulent few years, genetic testing company 23andMe is filing for bankruptcy. CEO Anne Wojcicki has resigned after three failed attempts at taking the company private and in a ...
View ArticleTempero Bio, led by ex-Novartis execs, gets $70M to reduce substance use...
A small Oakland, CA-based biotech hoping to take on the sprawling landscape of substance use disorders and addiction has reeled in $70 million. The drug development startup, named Tempero Bio, secured...
View ArticleBiogen plans to open new headquarters in Boston area in 2028
Biogen announced on Monday its plans to launch a new headquarters outside Boston, aiming to consolidate its research and development teams alongside its commercial operations. The building is located...
View ArticleNovo Nordisk pays $200M upfront for United Laboratories International...
Novo Nordisk is not immune to the trend of seeking obesity assets from China-based biotechs, and the Danish drugmaker will pay United Laboratories International Holdings $200 million upfront for an...
View ArticleSurrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund
Plus, news about CG Oncology, Opus Genetics and Valneva: Surrozen’s pivot and capital raise: The South San Francisco drug developer is scrapping clinical development in severe alcohol associated...
View ArticleTwo biotechs fail to beat or match Regeneron's Eylea in key trials
Opthea and Unity Biotechnology, which are both developing new drugs for eye diseases, were unable to beat or match aflibercept, the standard-of-care treatment that Regeneron markets as Eylea, in two...
View ArticleFDA's biologics chief stresses need for vaccine transmission data
Incorporating disease transmission data into vaccine trial designs could add to their benefit-risk calculus, even though it will likely make vaccines more costly to develop, Peter Marks, chief of the...
View ArticleAbbVie files suit against Genmab subsidiary ProfoundBio
AbbVie has accused a Genmab subsidiary of stealing trade secrets to build a potential competitor to its ovarian cancer treatment Elahere. In a lawsuit filed on Friday in Washington federal court,...
View ArticleTrump pharma tariffs: Details on impact and timing
President Donald Trump reiterated his plans to “at some point" put tariffs on pharmaceutical goods made outside the US, taking another step toward a trade policy that the industry has been trying to...
View Article